ATON PHARMA ANNOUNCES PARTNERSHIP WITH THE NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD)
--Partnership includes the management and administration of a Patient Assistance Program to ensure patient access to Aton products--
--Patient Assistance Program is available immediately to eligible patients through Aton Customer Service at 1-877-ATON-549--
Princeton, NJ – January 2, 2007 – Aton Pharma, Inc., a global specialty pharmaceutical company, announced today a strategic partnership with the National Organization for Rare Disorders (NORD) for the management and administration of a patient assistance program (PAP) to ensure patient access to the Aton product portfolio of essential treatments for rare diseases. The PAP program is designed to assist eligible patients in obtaining their medicines free of charge if they do not have prescription coverage and are unable to pay for their medicines. NORD will be responsible for the daily administration of the program, including the patient application process and product distribution to licensed physicians and pharmacies.
“ATON and NORD share a common vision – to assist individuals in obtaining life-saving or life-sustaining medicines in the treatment of rare diseases,” Said Michael Wells, president and CEO of Atom Pharma. “NORD’s customer focus, as well as detailed patient and disease understanding, will allow us to meet the needs of physicians and patients to provide the products and information necessary to improve patient outcomes and quality of life. NORD’s PAP programs have set the standards for fairness, equity, confidentiality and unbiased eligibility.”
“We are extremely pleased to be partnering with Aton and to be working closely with them in the treatment of rare diseases,” Said Abbey Meyers, president of NORD. “Our alliance with Aton allows us to expand our capabilities in helping patients with rare metabolic, neurological, cardiovascular and ophthalmic diseases. Eligible uninsured or under-insured patients will receive access to needed medicines that they may not have been able to obtain otherwise.”
Patients interested in learning more about the ATON PAP can request an application by calling Aton’s customer service line at 1-877-ATON-549 and pressing prompt #3 to reach the PAP.
About Aton Pharma, Inc.
Aton Pharma Inc., headquartered in Princeton, NJ, is a global specialty pharmaceutical company providing essential medicines to patients around the world. Aton’s mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton’s portfolio of seven products, with sales in 32 countries, targets rare and orphan metabolic, neurological, cardiovascular and ophthalmic diseases. Aton’s patient assistance program is designed to assist eligible patients worldwide in obtaining their medicines free of charge if they do not have prescription coverage and are unable to pay for their medicines. For more information, see www.atonrx.com.
About NORD
The National Organization for Rare Disorders (NORD), a 501(c)3 organization, is a unique federation of voluntary health organizations dedicated to helping people with rare "orphan" diseases and assisting the organizations that serve them. NORD is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and service. Established in 1983, NORD has served as the primary non-governmental clearinghouse for information on rare disorders. NORD also provides referrals to support groups and other sources of assistance. NORD provides information about diseases, referrals to patient organizations, research grants and fellowships, advocacy for the rare-disease community, and Medication Assistance Programs that help needy patients obtain certain drugs they could not otherwise afford. For more information about rare diseases and improving the lives of those affected, go to NORD’s web site at www.rarediseases.org.
Media Contact